NovoCure Limited (NVCR)
(Real Time Quote from BATS)
$18.28 USD
-0.20 (-1.08%)
Updated Jul 19, 2024 10:18 AM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVCR 18.28 -0.20(-1.08%)
Will NVCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCR
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
Other News for NVCR
CereVasc Announces Appointments of New Directors
PROCEPT BioRobotics Corp's Meteoric Rise: Unpacking the 25% Surge in Just 3 Months
First Week of December 20th Options Trading For NovoCure (NVCR)
NovoCure Shareholders Elect Directors and Endorse Key Proposals
Stocks with the highest and lowest liquidity - Goldman Sachs